Core Viewpoint - The company, Yimai Sunshine, remains optimistic about its long-term development prospects and is actively responding to investor concerns through share buybacks and management purchases, indicating strong confidence in its future [1][2] Group 1: Company Operations and Strategy - Yimai Sunshine confirms that its operations are normal and stable, with core business progress proceeding smoothly, adhering to its established strategy in medical data and artificial intelligence [1] - The management believes that recent market fluctuations are disconnected from the company's fundamentals, emphasizing that short-term volatility does not alter the long-term value [1] Group 2: Share Buyback and Management Purchase - The company plans to repurchase H-shares in the open market, with a total amount not exceeding 200 million HKD, based on recent achievements in regional medical imaging sharing centers and data services [1] - The buyback plan aims to stabilize the stock price and enhance shareholder returns, reflecting the company's confidence in its future development [1] - Chairman and CEO Chen Chaoyang purchased 59,500 shares at an average price of 10.10 HKD per share, totaling 600,950 HKD, increasing his ownership stake to 14.48% [2]

Core Viewpoint - The stock of Yipai Yangguang (2522.HK) has experienced a significant increase, rising over 11% in the last three trading days, driven by insider buying and positive developments in its business sectors [1] Group 1: Stock Performance - Yipai Yangguang's stock opened high today, reaching a peak increase of 4.4% to HKD 16.62 [1] - The stock has seen a cumulative rise of over 11% over the past three trading days [1] Group 2: Insider Buying - Company directors, including the Chairman and CEO Chen Chaoyang, purchased a total of 96,500 shares of the company's H-shares using personal funds on November 3 and 4, 2025 [1] - The decision for this increase in shareholding is based on the directors' confidence in the company's recent achievements in regional medical imaging sharing centers and data services [1] Group 3: Business Development and Strategic Alignment - The company has demonstrated strong capabilities in the "data + AI/algorithm + application scenario" full industry chain of smart medical imaging, which has been positively recognized [1] - The company's strategic layout in innovation aligns well with the State Council's implementation opinions on promoting and regulating the application of "AI + healthcare" issued on November 4, 2025 [1] - Directors believe that the current H-share price does not fully reflect the long-term investment value of the company [1]

Core Viewpoint - The company, Yipai Yangguang (02522), announced that several directors purchased a total of 96,500 H-shares in the open market, reflecting their confidence in the company's recent developments in medical imaging and AI applications [1] Group 1: Director Purchases - The chairman and CEO, Mr. Chen Chaoyang, along with other executive directors, purchased a total of 96,500 H-shares on November 3 and 4, 2025 [1] - The directors indicated that their decision to increase their holdings was based on the company's recent achievements in regional medical imaging sharing centers and data services [1] Group 2: Strategic Alignment and Confidence - The company's strategic layout in innovative fields aligns well with the State Council's recent implementation opinions on promoting and regulating AI in healthcare, issued on November 4, 2025 [1] - The directors expressed strong confidence in the company's future development prospects, believing that the current H-share price does not fully reflect the long-term investment value of the group [1] Group 3: Compliance and Public Holdings - The company maintains sufficient public shareholding as per the regulations of the Hong Kong Stock Exchange, even after the recent share purchases by the directors [1]